FB102 is a proprietary anti-CD122 monoclonal antibody being developed for autoimmune and autoimmune-related conditions. In other recent news, ...

FB102 is a proprietary anti-CD122 monoclonal antibody being developed for autoimmune and autoimmune-related conditions. In other recent news, Forte Biosciences, Inc. announced the results of its ...

The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad ...

DALLAS, June 23, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today ...

DALLAS, June 23, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...